Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 11/20 | 0.72 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.72 |
| ▸ | MAPK12 | P53778 | 4/20 | 0.72 |
| ▸ | MAPK11 | Q15759 | 4/20 | 0.72 |
| ▸ | DDR2 | Q16832 | 3/20 | 0.71 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.71 |
| ▸ | SRC | P12931 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | PTK2 | Q05397 | 6/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | BACE1 | P56817 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12245421 | 0.88 | MAPK14 (0.88) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| SCHEMBL2079824 | 0.85 | MAPK14 (0.81) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| SCHEMBL12245412 | 0.84 | MAPK14 (0.76) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| SCHEMBL13857353 | 0.84 | MAPK14 (0.80) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| SCHEMBL3292974 | 0.84 | MAPK14 (0.80) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| SCHEMBL27640941 | 0.84 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| SCHEMBL13296496 | 0.83 | MAPK14 (0.78) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| SCHEMBL12245411 | 0.83 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| SCHEMBL3293597 | 0.82 | MAPK14 (0.83) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| SCHEMBL3295412 | 0.82 | MAPK14 (0.83) | MAPK14MAPK13MAPK12MAPK11DDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1473292-A1 | Aromatic heterocyclic compounds as anti-inflammatory agents | Boehringer Ingelheim Pharmaceuticals, Inc. (US) | 2004-11-03 | — | — | EP | claimed |
| EP-1028953-A1 | AROMATIC HETEROCYCLIC COMPOUNDS AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2000-08-23 | — | — | EP | claimed |
| WO-1999023091-A1 | AROMATIC HETEROCYCLIC COMPOUNDS AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 1999-05-14 | — | — | WO | claimed |
| US-6432995-B1 | — | — | None | — | — | US | disclosed |
| EP-1473292-A1 | Aromatic heterocyclic compounds as anti-inflammatory agents | Boehringer Ingelheim Pharmaceuticals, Inc. (US) | 2004-11-03 | — | — | EP | disclosed |
| US-6432995-B2 | INHIBIT THE RELEASE OF INFLAMMATORY CYTOKINES SUCH AS INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR FROM CELLS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-08-13 | — | — | US | disclosed |
| US-20010039290-A1 | Aromatic heterocyclic compounds and their use as anti-inflammatory agents | REGAN JOHN R (US) | 2001-11-08 | — | — | US | disclosed |
| US-6228881-B1 | THIOPHENE DERIVATIVE CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2001-05-08 | — | — | US | disclosed |
| EP-1028953-A1 | AROMATIC HETEROCYCLIC COMPOUNDS AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2000-08-23 | — | — | EP | disclosed |
| US-6080763-A | INHIBIT THE RELEASE OF INFLAMMATORY CYTOKINES, E.G., TUMOR NECROSIS FACTOR AND INTERLEUKIN-1; USEFUL TO TREAT CHRONIC INFLAMMATORY DISEASE; AUTOIMMUNE DISEASES, E.G. RHEUMATOID ARTHRITIS, OSTEOPOROSIS; PYRAZOLYLUREAS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2000-06-27 | — | — | US | disclosed |
| WO-1999023091-A1 | AROMATIC HETEROCYCLIC COMPOUNDS AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 1999-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010039290-A1 | Aromatic heterocyclic compounds and their use as anti-inflammatory agents | IL1A, IL1B, TNF | MAPK14 1062/4885MAPK13 1221/4885MAPK12 797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.